Results : BP and lipid levels tended to come together soon in the post-trial period .
Conclusion : Benefits of BPL and lipid lowering on all-cause and cardiovascular mortality were persistent , but attenuated , after discontinuation of r and omized treatment , indicating the importance of continuing therapy
Objective : Persistent long-term benefits after discontinuation of treatment have been suggested for blood pressure-lowering and lipid-lowering treatment .
We conducted a systematic review to assess the long-term effects of  blood pressure ( BP ) lowering ( BPL ) and lipid lowering on all-cause and cardiovascular mortality after discontinuation of r and omized treatment .
Long-term effects on clinical outcomes of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation in the post coronary artery bypass graft trial. Post CABG Investigators.
BACKGROUND The Post Coronary Artery Bypass Graft Trial , design ed to compare the effects of 2 lipid-lowering regimens and low-dose anticoagulation versus placebo on progression of atherosclerosis in saphenous vein grafts of patients who had had CABG surgery , demonstrated that aggressive lowering of LDL cholesterol ( LDL-C ) levels to < 100 mg/dL compared with a moderate reduction to 132 to 136 mg/dL decreased the progression of atherosclerosis in grafts . Low-dose anticoagulation did not significantly affect progression . METHODS AND RESULTS Approximately 3 years after the last trial visit , Clinical Center Coordinators contacted each patient by telephone to ascertain the occurrence of cardiovascular events and procedures . The National Death Index was used to ascertain vital status for patients who could not be contacted . Vital status was established for all but 3 of 1351 patients . Information on nonfatal events was available for 95 % of surviving patients . A 30 % reduction in revascularization procedures and 24 % reduction in a composite clinical end point were observed in patients assigned to aggressive strategy compared with patients assigned to moderate strategy during 7.5 years of follow-up , P=0 . 0006 and 0.001 , respectively . Reductions of 35 % in deaths and 31 % in deaths or myocardial infa rct ions with low-dose anticoagulation compared with placebo were also observed , P=0.008 and 0.003 , respectively . CONCLUSIONS -The long-term clinical benefit observed during extended follow-up in patients assigned to the aggressive strategy is consistent with the angiographic findings of delayed atherosclerosis progression in grafts observed during the trial . The apparent long-term benefit of low-dose warfarin remains unexplained
Results : BP and lipid levels tended to come together soon in the post-trial period .
Conclusion : Benefits of BPL and lipid lowering on all-cause and cardiovascular mortality were persistent , but attenuated , after discontinuation of r and omized treatment , indicating the importance of continuing therapy
Objective : Persistent long-term benefits after discontinuation of treatment have been suggested for blood pressure-lowering and lipid-lowering treatment .
We conducted a systematic review to assess the long-term effects of  blood pressure ( BP ) lowering ( BPL ) and lipid lowering on all-cause and cardiovascular mortality after discontinuation of r and omized treatment .